Gilead's Kite Pharma Terminates $2.3B Cell Therapy Collaboration with Shoreline Biosciences

Recently, Gilead Sciences (Gilead Sciences) under theKite PharmaAnnounce the termination ofShoreline BiosciencesCollaboration in the field of universal cell therapy, with a total value exceeding23The $100 million R&D project has come to an end. A spokesperson for Gilead Sciences confirmed to the media that the collaboration had ended.2025The first quarter of the year has officially ended, andShorelineNo response has been made in this regard.

Tracing back to the starting point of cooperation, the two parties initially2021Year6Reached an agreement in the month, at that time distantKiteParticipateShoreline 4300Million USDAIt has only been two months since the last round of financing. According to the original agreement,ShorelineReceived an undisclosed upfront payment and is eligible to receive additional payments exceeding23USD milestone payment. The core direction of the collaboration is the engineering modification of natural killer cells (NKCells) to target hematologic malignanciesCARTargets, and in the future, the research scope may potentially expand to the field of macrophage engineering.

In fact, this cooperation in2025Signs of loosening had already emerged at the beginning of the year. This year1Month,ShorelineThe layoffs of employees related to this cooperation project suggest that the collaboration may face changes. This termination case is not an isolated one—just last month, Genentech, a subsidiary of Roche, also announced the termination of its partnership with Seattle.Adaptive BiotechnologiesCompany Value20The consecutive terminations of billion-dollar cell therapy collaborations have drawn industry attention to the R&D track of cell therapies.

Notably, the termination withShorelineThe cooperation does not mean that Gilead is scaling back its layout in the field of cell therapy. On the contrary, the biotech giant, headquartered in the San Francisco Bay Area, had just3.5Billion-dollar acquisition ofCAR-TProfessional CompanyInterius BioTherapeutics, and plans toInteriusThe in vivo platform is integrated intoKiteUnder its umbrella, it continues to deeply cultivate the field of cell therapy.

This timeKiteAndShorelineThe termination of the cooperation might be the result of divergences in development paths and goal achievement, while Gilead's acquisition of a new target to adjust its layout also reflects the characteristic of industry giants maintaining a flexible strategy in this field. In the future, cooperation and integration in the cell therapy sector will still be important highlights of industry development.

Reference:fierce biotech

●AbSeek™ Antibody Intelligent Computing Platform: Invite New Users to Earn Cash Red Packets, Double Tokens! Unlock All Paid Features with Ease!

●Senior Executives of Well-Known Pharmaceutical Companies Collectively Take a Pay Cut! Chairman's Annual Salary Halved...

●Another CAR-T Company Shuts Down!